1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Aptinyx Inc.
  6. Summary
    APTX   US03836N1037

APTINYX INC.

(APTX)
  Report
Delayed Nasdaq  -  05/17 01:09:26 pm EDT
0.6446 USD   +1.91%
05/12TRANSCRIPT : Aptinyx Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12APTINYX INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
05/12Aptinyx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/11/2022 05/12/2022 05/13/2022 05/16/2022 05/17/2022 Date
0.5701(c) 0.6(c) 0.6999(c) 0.6325(c) 0.6446 Last
821 163 163 104 136 370 347 083 146 828 Volume
-6.85% +5.24% +16.65% -9.63% +1.91% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -78,0 M - -
Net cash position 2022 58,7 M - -
P/E ratio 2022 -0,63x
Yield 2022 -
Sales 2023 16,7 M - -
Net income 2023 -72,4 M - -
Net Debt 2023 15,8 M - -
P/E ratio 2023 -0,83x
Yield 2023 -
Capitalization 42,8 M 42,8 M -
EV / Sales 2022 -
EV / Sales 2023 3,52x
Nbr of Employees 40
Free-Float 88,6%
More Financials
Company
Aptinyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of synthetic small molecules for the treatment of brain and nervous system disorders. The Company is targeting and modulating N-methyl-D-aspartate receptors (NMDArs), which are focused on brain and nervous system. It has three product candidates in clinical development in central nervous system... 
Sector
Pharmaceuticals
Calendar
05/26 | 10:00amShareholder meeting
More about the company
Ratings of Aptinyx Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D
More Ratings
All news about APTINYX INC.
05/12TRANSCRIPT : Aptinyx Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12APTINYX INC. Management's Discussion and Analysis of Financial Condition and Results o..
AQ
05/12Aptinyx Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/12Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Pro..
BU
04/29Aptinyx Presents Preclinical Data on NYX-783 in Models of PTSD at 2022 Society of Biolo..
BU
04/29Aptinyx Inc. Presents Preclinical Data on NYX-783 in Models of PTSD at 2022 Society of ..
CI
04/27Aptinyx to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
BU
04/21SVB Leerink Adjusts Aptinyx Price Target to $4 From $10, Maintains Outperform Rating
MT
04/20Aptinyx Announces Publication in Molecular Psychiatry Demonstrating Reduction of Sponta..
BU
04/20Aptinyx Inc. Announces Publication in Molecular Psychiatry Demonstrating Reduction of S..
CI
04/19APTINYX INC. : Other Events (form 8-K)
AQ
04/19Aptinyx Inc Announces Temporarily Paused the Initiation of its Phase 2b Study of the 15..
CI
04/14HC Wainwright Adjusts Price Target on Aptinyx to $2 From $8, Reiterates Buy Rating
MT
04/08BMO Capital Adjusts Price Target for Aptinyx to $6 From $12, Maintains Outperform Ratin..
MT
04/08Cantor Fitzgerald Lowers Aptinyx's Price Target to $5 From $11, Maintains Overweight Ra..
MT
More news
News in other languages on APTINYX INC.
05/12Aptinyx Inc. annonce ses résultats financiers pour le premier trimestre clos le 31 mars..
04/29Aptinyx Inc. présente des données précliniques sur NYX-783 dans des modèles de PTSD lor..
04/20Aptinyx Inc. annonce une publication dans Molecular Psychiatry démontrant la réduction ..
04/19Aptinyx Inc. annonce la suspension temporaire du lancement de son étude de phase 2b sur..
04/07MISE À JOUR SECTORIELLE : Les actions du secteur de la santé mènent la progression du marc..
More news
Analyst Recommendations on APTINYX INC.
More recommendations
Chart APTINYX INC.
Duration : Period :
Aptinyx Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APTINYX INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 0,63 $
Average target price 5,33 $
Spread / Average Target 743%
EPS Revisions
Managers and Directors
Andrew Kidd President, Chief Executive Officer & Director
Ashish Khanna Chief Financial & Business Officer
Norbert G. Riedel Executive Chairman
Harald Murck Vice President-Clinical & Medical Affairs
Elisha P. Gould Independent Director
Sector and Competitors
1st jan.Capi. (M$)
APTINYX INC.-76.31%43
CSL LIMITED-4.63%92 449
SAMSUNG BIOLOGICS CO.,LTD.-14.73%42 728
BIOGEN INC.-17.31%29 053
WUXI BIOLOGICS (CAYMAN) INC.-42.68%28 509
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-22.41%22 801